On April 4, 2023 TRANSGENE (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, reported that it will host a virtual Key Opinion Leader (KOL) event on Wednesday, April 19, 2023 at 12:00 pm ET / 6:00 pm CET (Press release, Transgene, APR 4, 2023, View Source [SID1234629823]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The KOL webinar will provide insights on TG4050 from expert medical oncologist Professor Christian Ottensmeier, MD, PhD, FRCP (University of Liverpool, La Jolla Institute for Immunology) who will also discuss the unmet medical need and outlook on treatment landscape for patients suffering from head and neck cancers. Prof. Ottensmeier’s presentation will be followed by a Q&A session.

In addition, Transgene’s management team will provide a company update, highlighting new Phase I data presented at AACR (Free AACR Whitepaper) on April 18, 2023, confirming the high immunogenicity and promising efficacy profile of TG4050, an individualized neoantigen cancer vaccine developed by Transgene in collaboration with NEC Corporation.

To register for the event, please click here.

Transgene will also present eight posters and have a booth (#310) at AACR (Free AACR Whitepaper) which is taking place in Orlando, Florida, on April 14-19, 2023.